- ISIN
- US64130M2098
- CUSIP
- 64130M209
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Sep 18, 2017
Highlights
- Market Cap
- $14.71M
- Enterprise Value
- $12.00M
- EPS (TTM)
- -$0.84
- Total Revenue (TTM)
- $9.72M
- Gross Profit (TTM)
- $5.30M
- EBITDA (TTM)
- -$6.72M
- Year Range
- $1.61 - $6.96
- Target Price
- $3.00
- ROA (TTM)
- -84.47%
- ROE (TTM)
- -123.63%
- Avg. Volume (1M)
- 50K
- Avg. Volume Value (1M)
- $123.76K
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NMTC Performance Chart
NeuroOne Medical Technologies Corporation (NMTC) is down 62.8% since the beginning of the year. At $2 per share, NMTC is trading 75.7% below its 52-week high of $7. Investors who bought $1,000 worth of NMTC shares 5 years ago would now be looking at an investment worth $59.
Loading charts...
Compare this symbol against anything
Returns By Period
NeuroOne Medical Technologies Corporation (NMTC) has returned -62.84% so far this year and -62.84% over the past 12 months.
NeuroOne Medical Technologies Corporation
- 1D
- -0.59%
- 1M
- -43.67%
- 6M
- -68.17%
- YTD
- -62.84%
- 1Y
- -62.84%
- 3Y*
- -35.71%
- 5Y*
- -43.17%
- 10Y*
- —
- ALL TIME*
- -34.51%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NMTC Monthly Returns History
Based on dividend-adjusted daily data since Sep 18, 2017, NMTC's average daily return is +0.04%, while the average monthly return is -0.45%.
Historically, 42% of months were positive and 58% were negative. The best month was Aug 2022 with a return of +116.1%, while the worst month was Mar 2022 at -45.0%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.
On a daily basis, NMTC closed higher 42% of trading days. The best single day was Feb 25, 2019 with a return of +51.9%, while the worst single day was Mar 28, 2022 at -46.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 16.75% | -24.25% | 15.83% | 0.88% | -24.47% | -14.37% | -44.41% | -62.84% | |||||
| 2025 | 39.24% | -3.04% | -23.75% | -26.65% | -2.00% | 11.00% | 15.30% | -2.29% | 16.28% | -10.87% | -12.27% | 9.10% | -8.22% |
| 2024 | -20.89% | -3.20% | -0.83% | -5.83% | -17.71% | -13.97% | -6.25% | 6.19% | 24.31% | -2.02% | -35.77% | 32.57% | -47.73% |
| 2023 | 20.83% | 11.03% | 0.00% | -4.35% | -21.43% | -0.83% | -15.00% | -16.62% | 4.69% | 1.07% | 61.13% | 8.97% | 31.67% |
| 2022 | 0.52% | 2.56% | -45.00% | -30.00% | 48.05% | -27.99% | 43.74% | 116.10% | -33.73% | -42.31% | 44.63% | -14.89% | -38.14% |
| 2021 | 40.13% | 29.55% | -14.04% | -8.16% | 9.45% | -10.26% | -28.36% | -25.26% | 11.27% | -28.61% | -24.07% | -9.39% | -58.81% |
Benchmark Metrics
NeuroOne Medical Technologies Corporation has an annualized alpha of 1.80%, beta of 0.62, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 18, 2017.
- This stock participated in 160.75% of S&P 500 Index downside but only -26.16% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.62 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 1.80%
- Beta
- 0.62
- R²
- 0.01
- Upside Capture
- -26.16%
- Downside Capture
- 160.75%
Return for Risk
Risk / Return Rank
NMTC ranks 7 for risk / return — above 7% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for NeuroOne Medical Technologies Corporation (NMTC) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NMTC | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.29 | ||
| Sortino ratioReturn per unit of downside risk | -3.39 | ||
| Omega ratioGain probability vs. loss probability | 0.84 | 1.25 | -0.41 |
| Calmar ratioReturn relative to maximum drawdown | -0.87 | 2.00 | -2.87 |
| Martin ratioReturn relative to average drawdown | -1.94 | 8.49 | -10.43 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NeuroOne Medical Technologies Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NeuroOne Medical Technologies Corporation was 98.98%, occurring on Jul 29, 2026. The portfolio has not yet recovered.
The current NeuroOne Medical Technologies Corporation drawdown is 98.96%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.98%Jul 2026 | 7y 5mo | — | 7y 5moFeb 2019 - now | — |
-42.11%Feb 2019 | 5mo 28d | 4d | 6mo 2dAug 2018 - Feb 2019 | — |
-23.65%Jul 2018 | 1mo 11d | 1mo 4d | 2mo 15dJun 2018 - Aug 2018 | — |
-17.50%Oct 2017 | 25d | 1mo 15d | 2mo 10dSep 2017 - Nov 2017 | — |
-12.50%Feb 2018 | 1d | 1mo 5d | 1mo 5dFeb 2018 - Mar 2018 | — |
Drawdown Indicators
| NMTC | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.98% | -56.78% | -42.20% |
Max Drawdown (1Y)Largest decline over 1 year | -74.06% | -9.10% | -64.96% |
Max Drawdown (3Y)Largest decline over 3 years | -85.68% | -18.90% | -66.78% |
Max Drawdown (5Y)Largest decline over 5 years | -94.92% | -25.43% | -69.49% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -98.96% | -1.58% | -97.38% |
Average DrawdownAverage peak-to-trough decline | -79.66% | -10.70% | -68.96% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.01% | 2.14% | +30.87% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NeuroOne Medical Technologies Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NeuroOne Medical Technologies Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NMTC relative to other companies in the Medical Devices industry. Currently, NMTC has a P/S ratio of 1.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NMTC in comparison with other companies in the Medical Devices industry. Currently, NMTC has a P/B value of 2.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NMTC
Add NeuroOne Medical Technologies Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NMTC